35
Avoid/minimize
use of other agents
(eg, drugs linked to
QTc prolongation).
Interrupt Sb
V
therapy
if QTc prolongation
(eg, if QTc >0.50
sec), concave ST
segments, clinically
relevant arrhythmias,
or moderate-to-severe
clinical pancreatitis.
resholds for
interrupting therapy
if asymptomatic
laboratory
abnormalities
(eg, elevated
aminotransferase
levels) should be
individualized.
Nonsteroidal
antiinflammatory
drugs may be used for
symptomatic therapy.
Avoid rigorous physical
activity.
Not formally
assigned to an
FDA pregnancy
category (see
Recs. 78-79)
Probably compatible
(see Recs. 78-79).
Interruption of
breastfeeding may
be prudent.
Patients with
advanced
immunosuppression
(eg, AIDS)
may have life-
threatening
pancreatitis or
cardiotoxicity
(see Recs. 61-
66). See Recs.
78-79 regarding
considerations
for other special
populations (eg,
children).
To minimize risk for
hypotension, infuse
drug over 1–2 h; keep
patient supine; check
vital signs before,
during, and aer
infusion (or injection)
until stable.
Avoid/minimize use of
other agents, including
nephrotoxic drugs.
Typically, NOT
warranted or
recommended
for
antileishmanial
treatment during
pregnancy.
Selection of a
different drug or
interruption of
breastfeeding may
be prudent.
Mitigation and
Management
Approaches
d,f
Pregnant
Patients
f,g
Breastfeeding
Patients
f,h
Comments
